Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines

Lourdes Ella Gonzalez-Santos,1 Raymond Oliva,1 Cecilia Jimeno,2 Eddieson Gonzales,3 Maria Margarita Balabagno,1 Deborah Ona,1 Jude Erric Cinco,4 Agnes Baston,4 Imelda Caole-Ang,7 Mia Fojas,8 Ruzenette Felicitas Hernandez,9 Ma. Cristina Macrohon-Valdez,10 Maria Theresa Rosqueta,11 Felix Eduardo Punzalan,12 Elmer Jasper Llanes12

1Division of Hypertension, Department of Medicine, University of the Philippines College of Medicine-Philippine General Hospital
2Department of Pharmacology and Toxicology, University of the Philippines College of Medicine
3Department of Internal Medicine, Batangas Medical Center, Philippines
4Department of Cardioiology, Perpetual Help DALTA Medical Center-Las Piñas City, Philippines
5Department of Cardiology, The Medical City, Pasig City, Philippines
6Department of Internal Medicine, Emilio Aguinaldo College Medical Center-Cavite, Philippines
7College of Medicine, Pamantasan ng Lungsod ng Maynila, Philippines
8Department of Biochemistry and Molecular Biology, University of the Philippines College of Medicine
9Department of Pediatrics, De La Salle University Medical Center and De La Salle Health Science Institute, College of Medicine, Dasmariñas, Cavite, Philippines
10Institute of Neurosciences, St. Luke’s Medical Center, Global City, Taguig, Philippines
11Philippine Heart Center
12Division of Cardiovascular Medicine, Department of Medicine, University of the Philippines College of Medicine-Philippine General Hospital

Abstract

Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually lower his risk for cardiovascular disease.

Key words: guidelines, dyslipidemia, cardiovascular prevention, familial hypercholesterolemia, diabetes mellitus

INTRODUCTION

The 2020 Clinical Practice Guidelines (CPG) for dyslipidemia is a collaboration of different stakeholders in the field of dyslipidemia, particularly the Philippine Heart Association (PHA), the Philippine Lipid and Atherosclerosis Society (PLAS), and the Philippine Society of Endocrinology, Diabetes, and Metabolism (PSEDM). Because of the different issues regarding special populations, the Philippine Society of Nephrology (PSN), Philippine Neurological Association (PNA), and the Philippine Pediatric Society (PPS) became part of this guideline formation. These guidelines are meant to provide physicians with a review of the latest available researches in the field of dyslipidemia to produce recommendations adaptable locally in the Philippines.

This is an update of the 2015 Clinical Practice Guidelines on the Management of Dyslipidemia in the Philippines (2015 CPG).1 The 2015 CPG covered topics on primary and secondary prevention, non-pharmacologic and pharmacologic treatment of dyslipidemia. When it was released, there were several questions on the management of special populations such as in kidney disease and the pediatric population. There were also issues on the adverse events of statin therapy. There were new clinical data that came out, particularly on ezetimibe, for secondary prevention that were not included in the 2015 CPG.

The objective of the 2020 CPG on Dyslipidemia is to provide evidence-based recommendations to effectively manage individuals with dyslipidemia. These recommendations aim to identify effective and feasible treatment regimens,

ISSN 0857-1074 (Print) | eISSN 2308-118x (Online)
Printed in the Philippines
Copyright © 2021 by Santos et al.
Received: September 14, 2020. Accepted: January 5, 2021.
Published online first: March 10, 2021.
https://doi.org/10.15605/jafes.036.01.01.

Vol. 36 No. 1 May 2021
www.asean-endocrinejournal.org

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/).
both non-pharmacologic and pharmacologic, in dyslipidemia treatment.

**METHODOLOGY**

Experts in the fields of dyslipidemia, cardiology, endocrinology, pediatrics, neurology, nephrology and clinical epidemiology assembled to comprise the technical research committee (TRC). They reviewed the recommendations in the 2015 CPG, gathered questions frequently asked in lipid fora conducted in the past five years and discussed challenges in cholesterol management in the Philippines before proposing critical clinical questions to be answered by the 2020 CPG. These questions were presented to the steering committee for comments. Clinical questions were formulated by identifying the specific population, intervention and outcomes for each question. Systematic searches for relevant studies were carried out.

Various clinical outcomes were rated and ranked using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) categories of importance. The clinical outcomes were rated numerically on a 1-to-9 scale following the GRADE categories, where a score of 7-9 is critical, 4-6 important; and 1-3, of limited importance (Table 1). According to GRADE, ranking outcomes by their relative importance can help to focus attention on those outcomes that are considered most important and help to resolve or clarify disagreements.

### Table 1. Clinical outcomes used in 2020 Clinical Guidelines

| Clinical Outcomes | GRADE Category | Score |
|-------------------|----------------|-------|
| Total mortality   | Critical       | 9     |
| Cardiovascular death | Critical   | 9     |
| Fatal and non-fatal myocardial infarction | Critical | 9     |
| Stroke or cerebrovascular disease | Critical | 9     |
| Major adverse CV events | Important | 7     |
| Coronary revascularization | Important | 6     |

Cardiovascular events were ranked as CRITICAL with a Score of 7. Coronary revascularization was assigned to be an IMPORTANT outcome with a GRADE PRO Score of 6. Additional important outcomes were added when deemed necessary for the particular clinical scenario (e.g., angina in ACS). Data on these six outcomes were extracted from the retrieved studies.

The TRC searched for all published studies, both local and international, pertaining to the clinical questions, with the use of electronic search engines and manual search. The literature search was conducted using the search engines PubMed, Scopus, Medline, Google Scholar, Cochrane reviews and other medical engines using search words relevant to each clinical question. The cut-off date of the search was February 1, 2020. Unpublished data were also retrieved, whenever possible. To formulate the recommendations, the Working Group used randomized controlled trials (RCTs), meta-analyses, and systematic reviews of studies carried out in individuals with or without established coronary heart disease/CVD and with or without risk factors for coronary heart disease/CVD, and diagnosed with elevated blood cholesterol. Prospective cohorts relevant to the clinical questions are discussed but were not included in the GRADE-PRO analysis.

Standardized tables were used to present the quality of the evidence and key results in a transparent and reproducible fashion. The statements were presented to a panel of experts who voted as to the level of recommendation using the Modified Delphi technique. This technique utilized a consensus strategy that systematically uses literature review, opinion of stakeholders and judgment of experts within a field to reach an agreement. It relies on the collective intelligence of group of members resulting in increased content validity.

### THE 2020 CLINICAL PRACTICE GUIDELINES

#### Clinical Question 1. Lifestyle Modifications

Among individuals with dyslipidemia, regardless of their present condition or risk profile, should lifestyle modification (i.e., reduced fat diet, smoking cessation, regular physical activity) be advised to reduce overall cardiovascular risk?

**Statements**

- For individuals at any level of cardiovascular risk, a low-fat, low-cholesterol diet, rich in fruits and vegetables, is **RECOMMENDED**.
- For individuals at any level of cardiovascular risk, cigarette smoking cessation is **STRONGLY RECOMMENDED**.
- For individuals at any level of cardiovascular risk, e-cigarette smoking/vaping CESSATION IS **RECOMMENDED**
- For individuals at any level of cardiovascular risk, adequate exercise is **RECOMMENDED**.

The practice guidelines recommend that lifestyle change play a major role in the management of dyslipidemia. A low-fat, low-cholesterol diet is recommended. We recommend that the Filipino individual with dyslipidemia utilize the Pinngang Pinyo that is advocated by the Food Nutrition and Research Institute of the Department of Health. It is a serving plate where half of the portion is of green and leafy vegetables, one-fourth serving of meat and the rest are fiber-rich carbohydrates.

The guidelines also strongly recommend that patients should stop smoking. The use of vaping or e-cigarettes is also not recommended for individuals with dyslipidemia. Exercising at least 150 minutes per week at moderate to high-intensity is also recommended.
PRIMARY PREVENTION

Clinical Question 2.1. Individuals with no prior ASCVD
• Among non-diabetic individuals without ASCVD but with multiple risk factors, should statin therapy be given?

Statement
• For individuals without diabetes aged ≥45 years with LDL-C ≥130 mg/dL AND ≥2 risk factors*, without atherosclerotic cardiovascular disease, statins are RECOMMENDED for the prevention of cardiovascular events.

In the 2015 CPG, we identified Risk Factor Counting as the method in identifying the risk of the Filipino individual for cardiovascular disease. We continue to recommend this as the available risk factor scores advocated by the different guidelines (e.g., ASCVD score) are not validated for Filipinos. The following risk factors were identified and if the individual has two (2) or more risk factors, (male sex, postmenopausal women, smoker, hypertension, BMI >25 kg/m², family history of premature CHD, proteinuria, and left ventricular hypertrophy) the benefit for statin therapy in primary prevention is fulfilled and statin therapy is indicated.

![Figure 1](image)

**Figure 1. Screening and treatment algorithm for the management of dyslipidemia.**

**Legend:**
* Risk factors: male, smoker, hypertension ≥140/90 mmHg, BMI 25 kg/m², family history of premature coronary heart disease, proteinuria, left ventricular hypertrophy and postmenopausal women
** The guideline recommends maximally-tolerated statin therapy to reach recommended target LDL-C levels

The use of statins for individuals with no clinical ASCVD (primary prevention) is recommended for patients aged 45 years and above with 2 or more risk factors with an LDL-C ≥130 mg/dL.

Clinical Question 2.2. Primary Prevention for Individuals with Diabetes Mellitus
• Among individuals with diabetes without ASCVD, should statins be recommended?

Statement
• For individuals with diabetes without evidence of ASCVD, statins are RECOMMENDED for primary prevention of cardiovascular events.

Evidence on the use of statins for primary prevention of cardiovascular outcomes were derived from 8 different clinical trials. The statin dose should be optimized to reach the LDL goal of less than 100 mg/dL for most persons with diabetes for primary prevention. For individuals with diabetes with >1 risk factor (refer to risk factors identified in primary prevention clinical question 2.1), LDL-C goal of less than 70 mg/dL is recommended. An LDL-C of <55 mg/dL should be attained for secondary prevention in individuals with diabetes who are at extremely high risk of having recurrent CV events due to the previous occurrence of major cardiovascular events such as myocardial infarction, unstable angina or CVD (stroke).

Clinical Question 3. Familial Hypercholesterolemia
• Among high risk individuals identified to have familial hypercholesterolemia, should statin therapy be initiated?

Statement
• For individuals identified to have familial hypercholesterolemia, statin therapy is STRONGLY RECOMMENDED for the prevention of cardiovascular events.

Familial hypercholesterolemia (FH) is a dominantly inherited gene disorder resulting from gene mutations in the LDL-receptor pathway that cause markedly elevated LDL-C from birth. Untreated FH leads to premature death from coronary artery disease due to accelerated atherosclerosis. Early diagnosis and treatment are vital in prevention of CV events in this high-risk population (Dutch Lipid Network Criteria) (Table 3). The recommendations in this local guideline is to give statin therapy for all identified FH patients for primary prevention. For familial hypercholesterolemia, the recommended statin therapy is the high-intensity dose of statin, with a target LDL-C of less than <70 mg/dL in FH patients without target organ damage, and <55 mg/dL for FH individuals with target organ damage.

Clinical Question 4. Dyslipidemia in the Pediatric Population
• Among pediatric population at risk for premature cardiovascular disease, should screening with fasting lipid profile be recommended?
Vol. 36 No. 1 May 2021

Lourdes Ella Gonzales-Santos, et al 2020 CPG for the Management of Dyslipidemia in the Philippines

### Clinical Question 5. Individuals with Chronic Kidney Disease

- Among individuals with chronic kidney disease who are not on dialysis, should statins be given to reduce CV risk?

### Statement

- Among individuals with chronic kidney disease who are not on dialysis, statins are **RECOMMENDED** for the prevention of cardiovascular events.

Dyslipidemia is common but not universal in CKD. Kidney dysfunction leads to a profound dysregulation of lipoprotein metabolism, resulting in multiple lipoprotein abnormalities. The recommendation in this local guideline is to give statins for individuals with CKD not on dialysis. For individuals who are on renal replacement therapy and post-transplant, this local guideline recommends referring patients to nephrologists for lipid management.

### SECONDARY PREVENTION

#### Clinical Question 6. Individuals with Acute Coronary Syndrome

- Among individuals with acute coronary syndrome (ACS), should statins be given?

### Statements

- For individuals with ACS, early high-intensity statin that is maximally-tolerated is **RECOMMENDED** and should not be discontinued.

- Statins should be given to ACS patients immediately

Timing of therapy is critical among patients with acute coronary syndrome. Early intervention is advocated to optimize recovery and minimize complications. The adage “time is muscle,” is based on the principle of the necessity for immediate action during the golden period in which myocardial ischemic damage is still potentially reversible or myocyte necrosis can still be contained and much of the myocardium in the ischemic penumbra can still be salvaged.

Evidence on the appropriate statin intensity for secondary prevention in individuals with ASCVD were obtained from four (4) trials10 that compared varying statin regimens. High-intensity statins reduce LDL-C by >50% compared to low-intensity statins which reduce LDL-C by less than 30% (Table 5).

---

### Table 3. Dutch lipid network criteria on the diagnosis of heterozygous familial hypercholesterolemia4

| Criteria | Points |
|----------|--------|
| Family history | 1 |
| First-degree relative with known premature* coronary and vascular disease, OR First-degree relative with known LDL-C level above the 95th percentile | 1 |
| First-degree relative with tendonous xanthomata and/or arcus cornealis OR Children aged less than 18 years with LDL-C level above the 95th percentile | 2 |

*Premature: ≤55 years in men; <60 years in women; LDL-C, low density lipoprotein cholesterol; FH, familial hypercholesterolemia; LDLR, low density lipoprotein receptor; Apo B, apolipoprotein B; PCSK9, proprotein convertase subtilisin/kexin type 9.

### Table 4. Risk factors for cardiovascular disease in the pediatric population6

| Traditional Risk Factors | Other conditions |
|--------------------------|------------------|
| Dyslipidemia | Familial hypercholesterolemia |
| Obesity | Chronic kidney disease |
| Diabetes mellitus (Type 1 or 2) | Kawasaki disease |
| Hypertension | Childhood cancer |
| Family history of premature CVD | Transplant vasculopathy |
| Smoke exposure | Certain congenital heart disease (e.g., coartation of the aorta, aortic stenosis) |
| | Cardiomyopathy |
| | Chronic inflammatory disorders |
| | HIV infection |
| | Adolescent depressive and bipolar disorders |

CVD, cardiovascular disease; HIV, human immunodeficiency virus

---

### Table 5. Statin treatment intensity

| Treatment intensity | % LDL-C reduction | Drug regimen |
|---------------------|------------------|--------------|
| Low intensity | <30 % | Fluvastatin 20 - 40 mg |
| | | Pravastatin 10 - 20 mg |
| Moderate intensity | 30% - 50% | Atorvastatin 10 - 20 mg |
| | | Fluvastatin 80 mg |
| | | Rosuvastatin 5 - 10 mg |
| | | Simvastatin 20 - 40 mg |
| | | Pravastatin 40 - 80 mg |
| | | Pitavastatin 2 - 4 mg |
| High intensity | >50% | Atorvastatin 40 - 80 mg |
| | | Rosuvastatin 20 - 40 mg |

---

LDL-C, low density lipoprotein cholesterol

---

www.asean-endocrinejournal.org

Vol. 36 No. 1 May 2021
NON-STATIN THERAPY

Clinical Question 7.1. Use of Ezetimibe
- Among individuals with ASCVD, should ezetimibe be given on top of statin therapy?

Statement
- For individuals without diabetes not at goal LDL-C, routinely adding ezetimibe on top of statin therapy is NOT RECOMMENDED for primary or secondary prevention of cardiovascular disease.
- Among individuals with ASCVD, omega fatty acids (EPA+DHA) given on top of statin therapy at goal LDL-C, but with persistently high triglyceride levels of 150-499 mg/dl, omega fatty acids (pure EPA) MAY be given.

Clinical Question 7.2. Use of Fibrates
- Among individuals with ASCVD, should fibrates be given on top of statin therapy once LDL-C goal is achieved?

Statements
- Among individuals with diabetes not at goal LDL-C, low HDL-C (<35 mg/dl) and persistently high triglycerides (>200 mg/dl) for prevention of CV disease.
- Among individuals with diabetes, with ≥1 risk factors / target organ damage.
- Among individuals with clinical ASCVD, omega fatty acids (EPA+DHA) given on top of statin therapy at goal LDL-C, but with persistently high triglyceride levels of 150-499 mg/dl, omega fatty acids (pure EPA) MAY be given.

Fourth Patient Groups

The 2020 CPG recommends that individuals be divided into four patient groups (Table 6). The cholesterol targets are based on clinical data and expert opinions of the voting panel.

Table 6. Cholesterol targets for different patient groups

| Patient Groups                                      | LDL-C Target  | HDL-C Target  | Triglyceride Target |
|-----------------------------------------------------|---------------|---------------|---------------------|
| Individuals with no clinical ASCVD                   | <130 mg/dL    | >40 mg/dL     | <150 mg/dl          |
| Individuals with DM                                  | <100 mg/dL    | >40 mg/dL     | <150 mg/dl          |
| With ≥1 risk factors / target organ damage           | <70 mg/dL     | >40 mg/dL     | <150 mg/dl          |
| With ASCVD                                           | <55 mg/dL     | >40 mg/dL     | <150 mg/dl          |
| Individuals with clinical ASCVD                      | <55 mg/dL     | >40 mg/dL     | <150 mg/dl          |
| FH without ASCVD or without major risk factor / target organ damage | <70 mg/dL     | >40 mg/dL     | <150 mg/dl          |
| FH with ASCVD or with ≥1 risk factors / target organ damage | <55 mg/dL     | >40 mg/dL     | <150 mg/dl          |

ASCVD, atherosclerotic cardiovascular disease; DM, diabetes mellitus; FH, familial hypercholesterolemia

STATIN ADVERSE EVENTS

Clinical Question 8. Use of Statin Therapy
- Among individuals taking statin therapy, what is the risk of developing adverse effects?
  a. Statin-associated Muscle Symptoms
  b. New-onset Diabetes
  c. Dementia / cognitive dysfunction / intracerebral hemorrhage

Statements
- Treatment with statins is associated with a low risk of developing statin-associated muscle symptoms (SAMS), but the benefits of cardiovascular risk reduction outweigh the risk (Figure 2).
- Treatment with statins is associated with an increased risk of new-onset diabetes mellitus, but the benefits...
of statin treatment for cardiovascular risk reduction outweigh the risk.

- Treatment with statins is not associated with the development of dementia and cognitive dysfunction
- Treatment with statins is not associated with an increased risk of intracerebral hemorrhage

ADDITIONAL TARGETS TO REDUCE CARDIOVASCULAR RISK

Clinical Question 9.1. Use of non-HDL-C

- Among individuals on statin therapy who have achieved their LDL-C goal, should non-high density lipoprotein cholesterol (non-HDL-C) be used as additional target to reduce CV events?

Statement

- Among individuals on statin therapy who have achieved their LDL-C goal, an elevated computed non-HDL-C may be used as an additional therapeutic target to further reduce CV events.

Non-HDL-C is the difference between the total cholesterol levels and HDL-C and quantifies all atherogenic lipoprotein particles. Target non-HDL in various guidelines set it as 30 mg/dL above target LDL-C. In patients with atherogenic dyslipidemia such as those with metabolic syndrome, type 2 diabetes mellitus and obesity, non-HDL-C determination is recommended as an additional tool providing a better estimate of risk beyond LDL-C. The non-fasting HDL computation has prognostic value in clinical trials as a therapeutic target.

Clinical Question 9.2. Use of Apolipoprotein B-100

- Among individuals on statin therapy who have achieved their LDL-C goal, should apolipoprotein B-100 be used as additional target to reduce CV events?

Statement

- Among individuals on statin therapy who have achieved their LDL-C goal, an elevated apolipoprotein B-100 may be used as an additional therapeutic target to further reduce CV event.

Limitations of the Guidelines

Several limitations were encountered during the process of creating the 2020 CPG. The evidence obtained from the trials only involved randomized controlled trials and some meta-analyses. Observational studies were only used as references. This approach, however, resulted in a comprehensive set of evidence-based clinical recommendations. The clinical trials did not include Filipino patients, thus analysis and grading of evidence were downgraded. Thus, we can only RECOMMEND the statements in this guideline. We hope in the future that more clinical trials be made with Filipino patients as subjects.

CONCLUSIONS

The clinical statements were made by the TRC and the recommendations revolve around the holistic management of dyslipidemia. Lifestyle modification should be recommended to all patients regardless of their CVD risk. Dosing of statin therapies should be based on individual risk factors. We recommend a lower LDL-C target, particularly for secondary prevention. The simplified algorithm was provided to serve as a quick reference in the management of dyslipidemia for clinicians.

The 2020 CPG is designed to be a guide for clinicians in managing dyslipidemia for the Filipino patient. This, however, should not replace sound clinical judgment by doctors and the ultimate decision for treatment should involve both clinician and the patient.

Acknowledgments

The authors would like to express their gratitude to the members of the steering committee and the representatives of the different medical organizations who comprised the expert panel, for their valuable inputs during the creation of the guidelines.

Steering Committee:

Adriel Guerrero (Philippine Lipid and Atherosclerosis Society)
Gilbert Villela (Philippine Heart Association)
Jeremy Jones Robles (Philippine Society of Endocrinology, Diabetes and Metabolism) Maaliddin Biruar (Philippine Society of Nephrology)
Roberto Mirasol (Philippine Lipid and Atherosclerosis Society)
Romeo Esagunde (Philippine Neurological Association)

Expert Panel

Leilani Asis (Philippine Society of Hypertension)
Federick Cheng (Philippine Lipid and Atherosclerosis Society)
Michael Villa (Philippine Society of Endocrinology, Diabetes and Metabolism)
Arlene Afsagi (Philippine Society of Nephrology)
Encarnita Limpin (Philippine College of Physicians)
Nemencio Nicodemus, Jr. (Philippine College of Physicians)
Florence Santos (Philippine Medical Association)
Jennifer Manzano (Philippine Neurological Association)
Ma. Bernadette Azcuet (Philippine Pediatric Society)
Jane Eflyn Bunyi (Philippine Academy of Family Physicians)
Emma Gaspar Trinidad (Philippine Heart Association)
Mildred Udarbe (Food and Nutrition Research Institute)
Romeo Merino (Manila Doctors Hospital)
Mark Anthony Cepeda (Philippine Health Insurance) [Non-voting]

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

Author Disclosure

Drs. Imelda Caole-Ang, Maria Margarita Balabagno, Agnes Baston, Ruzenette Felicianas Hernandez, Ma. Cristina Macrophon-Valdez and Maria Theresa Rosqueta have nothing to disclose.

Dr. Lourdes Ella Gonzalez-Santos reports personal fees from LRI-Therapharma, Sanofi-Aventis, Servier Philippines, Merck Sharpe and Dohme, Astra Zeneca, Menarini, Novartis, Natrapharm, Pascual, Amgen; research grant from Cardinal Santos Medical Center, outside the submitted work.

Dr. Raymond Oliva reports connection to Astellas Pharma Philippines, outside the submitted work.

Dr. Cecilia Jimeno is the Vice Editor-in-Chief of JAFES; reports speaking engagements from Natrapharm, Novartis, Servier Philippines, LRI-Therapharma; CME grant from OEP, Cathay; Advisory board of MSD, outside the submitted work.

Dr. Eddieson Gonzales reports personal fees for module development from Gertz Pharma; speaking engagements from Menarini, OEP, Zyudis, Ajanta, Astra Zeneca, Servier Philippines, Novartis and research grants from Innogen and Cathay Drug, outside the submitted work.

www.asean-endocrinejournal.org
References

1. Philippine Lipid and Atherosclerosis Society / Philippine Heart Association / Philippine Society of Endocrinology, Diabetes and Metabolism. 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines. https://www.philheart.org/index.php/guidelines/142-dyslipidemia-guidelines. Accessed February 1, 2020.

2. GRADE: your evidence and improve your guideline in development in health care. https://gradepro.org

3. Breda Eubank, Mohtadi NG, Laffe MR, et al. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol. 2016;16:36. PMCID: PMC4879724. https://doi.org/10.1186/s12874-016-0165-8.

4. Pijman A, Hijjigen R, Vlihagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209(1):189–94. PMID: 19818960. https://doi.org/10.1016/j. atherosclerosis.2009.09.014.

5. Expert Panel on Integrated Guidelines for cardiovascular health and risk reduction in children and adolescents. National Heart, Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011;128(Suppl 5):S213-56. PMID: 22084329. PMCID: PMC4536582. https://doi.org/10.1542/ peds.2009-2107C.

6. Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children. J Clin Endocrinol Metab. 2014;99(9):3093-102. PMCID: 24845708. https://doi.org/10.1210/jc.2013-3860.

7. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet. 2010;376(9753):1658–69. PMID: 20167805. PMCID: PMC2988223. https://doi.org/10.1016/S0140-6736(10)60310-8.

8. d’Evelyn MA, Blazing MA, Vlihagen SN, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16. PMID: 15357732. https://doi.org/10.1001/jama.292.11.1307.

9. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. PMID: 15755765. https://doi.org/10.1056/ NEJMoa050461.

10. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA. 2005;294(19):2437-45. PMID: 16287954. https://doi.org/10.1001/jama. 294.19.2437.